Page last updated: 2024-09-04

levofloxacin and n-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1h-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide

levofloxacin has been researched along with n-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1h-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide in 1 studies

Compound Research Comparison

Studies (levofloxacin)	Trials (levofloxacin)	Recent Studies (post-2010) (levofloxacin)	Studies (n-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1h-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide)	Trials (n-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1h-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide)	Recent Studies (post-2010) (n-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1h-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide)
4,346	581	2,209	17	7	16

Protein Interaction Comparison

Protein	Taxonomy	levofloxacin (IC50)	n-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1h-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide (IC50)
Neutrophil elastase	Homo sapiens (human)		0.012

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Jones, P; Leidy, NK; Murray, LT; Sethi, S	1

Trials

1 trial(s) available for levofloxacin and n-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1h-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide

Article	Year
Performance of the EXAcerbations of chronic pulmonary disease tool patient-reported outcome measure in three clinical trials of chronic obstructive pulmonary disease. Annals of the American Thoracic Society, 2014, Volume: 11, Issue:3 Topics: Aged; Anti-Bacterial Agents; Bronchodilator Agents; Cohort Studies; Female; Humans; Levofloxacin; Male; Medical Records; Middle Aged; Outcome Assessment, Health Care; Pulmonary Disease, Chronic Obstructive; Pyridones; Reproducibility of Results; Severity of Illness Index; Sulfones; Surveys and Questionnaires; Time Factors	2014

Article

Year

Performance of the EXAcerbations of chronic pulmonary disease tool patient-reported outcome measure in three clinical trials of chronic obstructive pulmonary disease.

Annals of the American Thoracic Society, 2014, Volume: 11, Issue:3

Topics: Aged; Anti-Bacterial Agents; Bronchodilator Agents; Cohort Studies; Female; Humans; Levofloxacin; Male; Medical Records; Middle Aged; Outcome Assessment, Health Care; Pulmonary Disease, Chronic Obstructive; Pyridones; Reproducibility of Results; Severity of Illness Index; Sulfones; Surveys and Questionnaires; Time Factors

2014